FDA Reform Bills Grow Similar As House/Senate Conference Committee Nears
Executive Summary
The recently passed House FDA reform bill (H.R. 2900) includes several last-minute changes that bring it closer to the Senate version (S. 1082), suggesting Congressional efforts to ease the prospective merge of the bills in the upcoming Conference Committee
You may also be interested in...
Drug Industry Boosts Lobbying Coffers; Amgen Doubles Its Expenditures
Lobbyists for the pharmaceutical industry have had plenty of work this year as Congress pushed forward legislation to overhaul the patent system, mandate lower drug prices for Medicare, and clear the way for approval of generic biologics
Drug Industry Boosts Lobbying Coffers; Amgen Doubles Its Expenditures
Lobbyists for the pharmaceutical industry have had plenty of work this year as Congress pushed forward legislation to overhaul the patent system, mandate lower drug prices for Medicare, and clear the way for approval of generic biologics
FDARA Citizen Petition Provisions No “Silver Bullet,” Bradshaw Tells GPhA
Provisions in FDA reform legislation that aim to limit the impact of citizen petitions on generic drug approvals are unlikely to provide the relief the generic industry seeks, according to outgoing FDA Chief Counsel Sheldon Bradshaw